Lennox Gastaut Syndrome clinical trials

Explore recruiting lennox gastaut syndrome clinical trials.

Recruiting lennox gastaut syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lennox Gastaut Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open- Label Extension

Spain, Hungary, Italy, Germany, Poland, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Non-randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine.

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome

Italy, Spain, Hungary, Romania, Czechia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome

Spain, Netherlands, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

Latvia, Germany, Netherlands, France, Spain, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures

Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lennox Gastaut Syndrome trials by city

Lennox Gastaut Syndrome in Toronto Lennox Gastaut Syndrome in Vancouver Lennox Gastaut Syndrome in Montreal Lennox Gastaut Syndrome in Calgary Lennox Gastaut Syndrome in Edmonton Lennox Gastaut Syndrome in Ottawa Lennox Gastaut Syndrome in Winnipeg Lennox Gastaut Syndrome in Quebec City Lennox Gastaut Syndrome in Hamilton Lennox Gastaut Syndrome in Kitchener Lennox Gastaut Syndrome in London Lennox Gastaut Syndrome in Halifax Lennox Gastaut Syndrome in New York Lennox Gastaut Syndrome in Los Angeles Lennox Gastaut Syndrome in Chicago Lennox Gastaut Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease